Adam S. Kibel
YOU?
Author Swipe
Impact of Age, Marital Status, Smoking, and Alcohol Consumption on Urinary and Sexual Function in Prostate Cancer Patients Treated With Radical Prostatectomy: A Prospective Cohort Study Open
Urinary function scores recover to levels approaching baseline by 12 months post-RP. Sexual function scores do not recover to baseline levels by 12 months post-RP for any group and are lower for participants who are older, unmarried, or sm…
View article: Disparities in tissue-based biomarker testing among US Medicare beneficiaries with prostate cancer
Disparities in tissue-based biomarker testing among US Medicare beneficiaries with prostate cancer Open
Background Personalized therapeutic approaches for localized prostate cancer have evolved significantly, with tissue-based biomarker tests supplementing traditional risk stratification tools. However, national testing patterns and geograph…
Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancer Open
Current treatments for advanced prostate cancer (PCa) primarily target the androgen receptor (AR) pathway. However, the emergence of castration-resistant prostate cancer (CRPC) and resistance to AR pathway inhibitors (APPIs) remains ongoin…
View article: Feasibility of <scp>MRI</scp>‐Guided Transperineal Implantation of Microdevices for Drug Delivery and Response Assessment in Prostate Cancer
Feasibility of <span>MRI</span>‐Guided Transperineal Implantation of Microdevices for Drug Delivery and Response Assessment in Prostate Cancer Open
Background Prostate cancer (PCa) treatment often involves systemic therapies with varying mechanisms of action, affecting individuals differently. Implantable microdevices (IMDs) are designed to test multiple drugs within a patient's tumor…
View article: Specificity of a polygenic score for aggressive prostate cancer
Specificity of a polygenic score for aggressive prostate cancer Open
To address the concern that polygenic hazard scores for prostate cancer (PCa) might not distinguish between indolent and aggressive disease, we performed case-only analyses using a 601-variant polygenic score (PHS601). We hypothesized that…
Profiling of early-onset bladder cancer identifies key genomic alterations and potential targets Open
Younger patients with bladder cancer typically have fewer environmental exposures or risk factors, suggesting molecular pathways implicated in early-onset disease differ from older patients. Dissecting the genomic profile of early-onset tu…
View article: From a genomic risk model to clinical trial implementation in a learning health system: the ProGRESS Study
From a genomic risk model to clinical trial implementation in a learning health system: the ProGRESS Study Open
Background As healthcare moves from a one-size-fits-all approach towards precision care, individual risk prediction is an important step in disease prevention and early detection. Biobank-linked healthcare systems can generate knowledge ab…
View article: Postprostatectomy Radiotherapy Timing and Long-Term Health-Related Quality of Life
Postprostatectomy Radiotherapy Timing and Long-Term Health-Related Quality of Life Open
Importance The association between radiotherapy (RT) timing after radical prostatectomy and long-term patient-reported health-related quality of life (HRQOL) in men with prostate cancer is unknown. Objective To measure long-term HRQOL in m…
View article: Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer Open
As compared with standard lymphadenectomy, extended lymphadenectomy did not result in improved disease-free or overall survival among patients with muscle-invasive bladder cancer undergoing radical cystectomy and was associated with higher…
View article: When is prostate cancer really cancer?
When is prostate cancer really cancer? Open
Prostate cancer (PC) is a major cause of cancer-related deaths worldwide, with far more diagnoses than deaths annually. Recent discussions have challenged whether Grade Group 1 (GG1) PC should be labeled “cancer” due to its indolent nature…
Acute BRCAness Induction and AR Signaling Blockage through CDK12/7/9 Degradation Enhances PARP Inhibitor Sensitivity in Prostate Cancer Open
Current treatments for advanced prostate cancer (PCa) primarily target the androgen receptor (AR) pathway. However, the emergence of castration-resistant prostate cancer (CRPC) and resistance to AR pathway inhibitors (APSIs) remains ongoin…
View article: Early Prostate Cancer Deaths Among Men With Higher vs Lower Genetic Risk
Early Prostate Cancer Deaths Among Men With Higher vs Lower Genetic Risk Open
Importance Prostate cancer, a leading cause of cancer death among men, urgently requires new prevention strategies, which may involve targeting men with an underlying genetic susceptibility. Objective To explore differences in risk of earl…
View article: Insulin resistance during androgen deprivation therapy in men with prostate cancer
Insulin resistance during androgen deprivation therapy in men with prostate cancer Open
Background Androgen deprivation therapy (ADT) in prostate cancer (PCa) has been associated with development of insulin resistance. However, the predominant site of insulin resistance remains unclear. Methods The ADT & Metabolism Study was …
View article: Estimating the impact of enhanced care at minority‐serving hospitals on disparities in the treatment of breast, prostate, lung, and colon cancers
Estimating the impact of enhanced care at minority‐serving hospitals on disparities in the treatment of breast, prostate, lung, and colon cancers Open
Background The objective of this study was to quantify disparities in cancer treatment delivery between minority‐serving hospitals (MSHs) and non‐MSHs for breast, prostate, nonsmall cell lung, and colon cancers from 2010 to 2019 and to est…
Agent orange exposure and prostate cancer risk in the million veteran program Open
Background: The US government considers veterans to have been exposed to Agent Orange if they served in Vietnam while the carcinogen was in use, and these veterans are often deemed at high risk of prostate cancer (PCa). Here, we assess whe…
View article: Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer
Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer Open
Importance Benefits of prostate cancer (PCa) screening with prostate-specific antigen (PSA) alone are largely offset by excess negative biopsies and overdetection of indolent cancers resulting from the poor specificity of PSA for high-grad…
Impact of Family History and Germline Genetic Risk Single Nucleotide Polymorphisms on Long-Term Outcomes of Favorable-Risk Prostate Cancer Open
Family history of prostate, breast, or pancreatic cancer and/or a 19q13 germline risk allele are associated with an elevated risk of prostate cancer‒specific death among favorable-risk patients. These findings have implications for how fam…
Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer Open
Importance Multiple strategies integrating magnetic resonance imaging (MRI) and clinical data have been proposed to determine the need for a prostate biopsy in men with suspected clinically significant prostate cancer (csPCa) (Gleason scor…
View article: Provider Perceptions of an Electronic Health Record Prostate Cancer Screening Tool
Provider Perceptions of an Electronic Health Record Prostate Cancer Screening Tool Open
Objectives We conducted a focus group to assess the attitudes of primary care physicians (PCPs) toward prostate-specific antigen (PSA)-screening algorithms, perceptions of using decision support tools, and features that would make such too…
View article: A Provider-Facing Decision Support Tool for Prostate Cancer Screening in Primary Care: A Pilot Study
A Provider-Facing Decision Support Tool for Prostate Cancer Screening in Primary Care: A Pilot Study Open
Objectives Our objective was to pilot test an electronic health record-embedded decision support tool to facilitate prostate-specific antigen (PSA) screening discussions in the primary care setting. Methods We pilot-tested a novel decision…
Combining magnetic resonance imaging with a multi-ancestry polygenic risk score to improve identification of clinically significant prostate cancer Open
Multi-parametric magnetic resonance imaging (mpMRI) has emerged as an important tool for identifying clinically significant prostate cancer. We examined if the addition of a 400-variant multi-ancestry polygenic risk score (PRS) to mpMRI ha…
View article: Postradical prostatectomy prostate‐specific antigen outcomes after 6 versus 18 months of perioperative androgen‐deprivation therapy in men with localized, unfavorable intermediate‐risk or high‐risk prostate cancer: Results of part 2 of a randomized phase 2 trial
Postradical prostatectomy prostate‐specific antigen outcomes after 6 versus 18 months of perioperative androgen‐deprivation therapy in men with localized, unfavorable intermediate‐risk or high‐risk prostate cancer: Results of part 2 of a randomized phase 2 trial Open
Background Patients with localized, unfavorable intermediate–risk and high‐risk prostate cancer have an increased risk of relapse after radical prostatectomy (RP). The authors previously reported on part 1 of this phase 2 trial testing neo…
View article: Evidence-Based Analysis of the Critical Steps of Radical Cystectomy for Bladder Cancer
Evidence-Based Analysis of the Critical Steps of Radical Cystectomy for Bladder Cancer Open
Radical cystectomy (RC) is an integral part of the management of patients with advanced-stage bladder cancer. This major oncologic operation is prone to complications resulting in morbidity and mortality. We analyzed the critical steps of …